STAT Plus: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
Amgen
Amgen, a California-based multinational biopharmaceutical company, had 2022 revenues in excess of $26 billion. Amgen products include Aranesp, an anemia treatment; Enbrel, used against autoimmune conditions, and Neulasta for chemotherapy patients.
Latest
STAT Plus: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
STAT Plus: Amgen goes all in on injectable obesity drug as it scraps early-stage pill
STAT Plus: Amgen sues Colorado over its prescription drug affordability board
STAT Plus: At health care’s biggest investor conference, AI’s high hopes collided with skepticism
STAT Plus: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
STAT Plus: Amgen reports first clinical data on new targeted cancer therapy
STAT Plus: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
All Coverage
advertisement
